Following informed consent, patients with pterygium who meet all eligibility criteria will be randomized to an 84-day double-blinded study to measure the safety and efficacy of the study drug as compared to placebo.
The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.